Stocks stumbled to kick off the week 📉

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. 

Welcome back from the mid-week break. Here’s what moved the market today.

Markets 📈

The market opened the trading week with mixed results today. The Down & Russ2K edged higher, while the Nasdaq suffered a sudden sell-off. The S&P 500 also closed lower.

High-Growth Tech Innovator Expanding Fast

This company has quadrupled its sales in two years and secured major partnerships.

After years of quietly plugging away, its breakout moment could be drawing near, and there’s still time to position yourself.

Get All the Details Here »

» Want an Ad-Free Experience + Top Growth Stock Picks? Upgrade Now! 

Market-Moving News 📈

Novo Nordisk to Build $4.1 Billion Facility in North Carolina to Boost Wegovy, Ozempic Production 🏭

Novo Nordisk announced plans to invest $4.1 billion in a new manufacturing plant in Clayton, North Carolina. This facility aims to enhance the supply of its popular weight loss drug Wegovy, diabetes treatment Ozempic, and other injectable therapies, addressing the high demand that has led to intermittent shortages.

Expanding Manufacturing 🛠️
The new plant will focus on filling and packaging syringes and injection pens. Doug Langa, head of North American operations, emphasized the investment's role in serving more patients and furthering U.S. manufacturing capabilities. Construction of the 1.4 million-square-foot facility has begun, with completion expected between 2027 and 2029. The site will employ 1,000 workers, adding to the 2,500 already at Novo Nordisk's North Carolina facilities.

Current Operations 🌐
Novo Nordisk operates two existing sites in Clayton for fill and finish work and the production of Rybelsus, a diabetes pill. The company also has a facility in Durham for manufacturing and packaging oral drugs. Additionally, Novo Nordisk has 12 other production sites across Denmark, France, China, Japan, Algeria, Brazil, Iran, and Russia.

Addressing Shortages 📈
Three lower doses of Wegovy are currently in shortage in the U.S. due to high demand. About 35,000 U.S. patients start Wegovy each week, up from 27,000 in May. The company is carefully managing the release of lower doses to ensure continuity for existing patients progressing to higher doses.

Future Plans 🔄
Rival Eli Lilly is also investing heavily to increase the production of its GLP-1s, Zepbound and Mounjaro, for weight loss and diabetes, with several plants in North Carolina. Novo Nordisk’s significant investment highlights the ongoing competition and the need to scale production to meet growing demand for these therapies.

MicroAlgo [MLGO] $15.00 (+288%)
rallied after Masaya Otsuka reported a 13.56% passive stake in the company during Friday’s after-market.

Alimera [ALIM] $5.54 (+75.8%)
agreed to be acquired by ANI Pharmaceuticals [ANIP +7.3%] in a cash and CVR deal that pays roughly $5.50 per share.

Nexalin [NXL] $2.31 (+40.8%)
extended its gains from Friday, when it announced a new U.S. patent for its Deep Intracranial Frequency Stimulation device to treat Alzheimer’s and dementia.

Lead Real Estate [LRE] $3.08 (64.6%)
announced plans for a new “premium series” hotel and a special cash dividend payable Sep. 30th, 2024.

Regulus Therapeutics [RGLS] $2.05 (18.3%)
closed its business combination with Anew Medical and will begin trading under symbol WENA at Monday’s open.

CareMax [CMAX] $2.16 (18.1%)
announced a limited waiver and a sixth amendment to a certain credit agreement early this morning.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback from our members!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Text ELITESTOCKS to 47121 or click here to get our alerts on your mobile device, and never miss another fast-moving stock!

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.

A.I. Pioneer Warns: “I thought we had
more time…”

A radical new A.I. development is about to blindside millions of Americans.

This early A.I. pioneer just issued an urgent warning explaining everything.

Click here to see his new video for yourself.